Flashback Technologies Receives Award From U.S. Army For Hemorrhage Early Detection Monitor

    DENVER, CO, December 07, 2020 /24-7PressRelease/ -- Flashback Technologies Inc., announced today it has been selected by the U.S. Army Medical Materiel Development Activity (USAMMDA) to receive $1.4 million through a Medical Technology Enterprise Consortium (MTEC) award to support continued development of the Company's novel vital sign, The Compensatory Reserve Index (CRI).

MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. Flashback's award falls under an effort to support the development of new technologies that provide early detection of hemorrhage and the risk of hemorrhagic shock.

Hemorrhage is a leading cause of preventable death in both military and civilian trauma settings. According to the MTEC, hemorrhage, or life-threatening blood loss, has accounted for more than 33% of prehospital deaths and 50% of deaths occurring within 24 hours after a traumatic injury. Around half of all preventable combat-related deaths that occur before reaching a military treatment facility are hemorrhage-related.

"A study of 4,596 battlefield fatalities from Operation Iraqi Freedom and Operation Enduring Freedom determined that hemorrhage accounted for 91% of potentially survivable fatalities occurring prior to arrival at a [medical facility]," MTEC added.

Flashback Technologies is in commercial development of a new vital sign, the Compensatory Reserve Index (CRI). The FDA cleared technology enables noninvasive, real-time monitoring of central volume status and a subject's proximity collapse due to hemorrhage or dehydration. The technology is currently available on two Flashback devices. The company is in discussions with medical device manufacturers to integrate CRI software into their platforms.

The award will fund a large-scale pre-hospital study with a leading emergency medicine research institution. The project will also support regulatory expansion of the company's current FDA indications for use and other product development efforts.

"We are honored and humbled to continue our collaboration with the US Army," said Flashback CEO, Kiernan McGuire. "The notion that our work can help save the lives of our men and women in uniform brings mission to our work each and every day."

About Flashback Technologies Inc.
Flashback Technologies uses advanced machine learning technologies to develop groundbreaking vital sign monitoring solutions that provide novel insight for caregivers and better outcomes for patients.

Flashback's founder and Chief Medical Officer is Dr. Steven Moulton, Director of Pediatric Trauma and Burn Services at Children's Hospital Colorado and Professor of Surgery at the University of Colorado, School of Medicine. Dr. Moulton is the State of Colorado Vice-Chair for the American College of Surgeons, Committee on Trauma (ACS COT). His research efforts span the fields of trauma and burn care, resuscitation and hemodynamic monitoring.

The company's first commercial product is The Compensatory Reserve Index (CRI). Due to a variety of compensatory mechanisms, standard vital signs do not deteriorate with central volume loss due to hemorrhage or dehydration until the patient is near collapse and at risk of hypovolemic shock. CRI provides insight into intravascular volume loss well in advance of traditional vital signs such as HR, ECG, BP, SpO2 and SV. Hemorrhage is a leading cause of preventable death in both civilian and military trauma. Early detection and intervention enabled by CRI can mitigate risk, improve outcomes and focus resources on the most critical cases.

To date, a solid bedrock of over 40 peer reviewed papers have been published on CRI. Leading research partners have included Duke Medical Center and U.S. Army Institute of Surgical Research.

To learn more, visit http://www.flashbacktechnologies.com or email:
[email protected]

About USAMMDA
USAMMDA is a subordinate command of the USAMRDC, under the Army Futures Command. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for developing and delivering critical products designed to protect and preserve the lives of Warfighters across the globe. These products include drugs, vaccines, biologics, devices and medical support equipment intended to maximize survival of casualties on the battlefield.

To learn more, visit https://www.usammda.army.mil/

About Medical Technology Enterprise Consortium
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit www.mtec-sc.org.

The views expressed in this news release/article are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

# # #